

Date: 2011-Sep-15

To: Centre Representatives
Ethics Representatives
Contact Clinical Research Associates

From: Anna Sadura, Trial Management, NCIC Clinical Trials Group

**RE: PERMANENT TRIAL CLOSURE NOTICE FOR
PHASE I/II/III INTERGROUP LED STUDIES**

Dear Participants,

We are writing today to inform you of the CALGB decision to Terminate/Permanently close the following study. This trial is now complete and no longer requires action including cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals.

Effective immediately, data submission and REB approval for the following Intergroup-led trial is no longer required:

<i>Disease Site</i>	<i>Trial Code</i>	<i>Contact</i>
Hematology	CL1	Christine Bertrim cbertrim@ctg.queensu.ca

Please notify your REB of any outstanding ethics documents for the trial above and of the final completion of this trial. A copy of this notification must be kept on file at your centre for auditing purposes. Please note that this memorandum supersedes any protocol instructions requiring the continued follow-up of patients and submission of data.

Please note that although this trial is permanently closed, trial documents must still be retained. NCIC CTG will continue to notify participating centres when trial related records no longer need to be retained in accordance with applicable regulations. Please visit the following web site for further information: <http://www.ctg.queensu.ca/private/ethics/RecordsRetention.pdf>

Yours sincerely,



Manager, Trial Conduct
NCIC CTG Clinical Trials Group
asadura@ctg.queensu.ca